interleukin-10
Recombinant proteinexperimental
Interleukin 10 (IL-10), also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine. In humans, interleukin 10 is encoded by the IL10 gene. IL-10 signals through a receptor complex consisting of two IL-10 receptor-1 and two IL-10 receptor-2 proteins. Consequently, the functional receptor consists of four IL-10 receptor molecules. IL-10 binding induces STAT3 signalling via the phosphorylation of the cytoplasmic tails of IL-10 receptor 1 + IL-10 receptor 2 by JAK1 and TYK2 respectively. — Wikipedia
Clinical trial activity
14 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 1998 (NCT00001761)
Timeline
Indications
Studied for
- Bile Duct Diseases · Phase 2
- Biliary Tract Diseases · Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1
- Cicatrix · Phase 2
- Colorectal Neoplasms · Phase 1
- Gallbladder Diseases · Phase 2
- Granulomatosis with Polyangiitis · Phase 1
- Healthy Volunteers · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Diseases · Phase 2
- Pancreatic Neoplasms · Phase 3
- Pancreatitis · Phase 2
- Prostatic Neoplasms · Phase 1
- Psoriasis · Phase 2
- Vasculitis · Phase 1
- Wound Healing · Phase 2
Mechanism of action
- IL-10 receptorAGONIST
IL-10 receptor agonist
- Interleukin-10Supplementation
IL10 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaInterleukin 10 ↗
- ChEMBLCHEMBL4297771 ↗
- ChEMBLCHEMBL3989992 ↗
Also known as
- am0010
- il-10
- il-10
- il-10
- interleukin-10
- interleukin-10
- prevascar
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03382912 | Phase 2 | Mar 14, 2018 | ARMO BioSciences |
| NCT03382899 | Phase 2 | Feb 22, 2018 | ARMO BioSciences |
| NCT04194892 | Phase 1 | Jan 19, 2018 | ARMO BioSciences, Eli Lilly |
| NCT03381547 | Phase 1 | Jan 12, 2018 | ARMO BioSciences |
| NCT03267732 | Phase 1 | Sep 5, 2017 | ARMO BioSciences |
| NCT02923921 | Phase 3 | Nov 1, 2016 | ARMO BioSciences |
| NCT02009449 | Phase 1 | Nov 1, 2013 | ARMO BioSciences |
| NCT01115868 | Phase 1 | Apr 1, 2010 | RenovoRx |
| NCT00630006 | N/A | Jan 1, 2007 | Kaohsiung Medical University |
| NCT00984646 | Phase 2 | Apr 1, 2005 | RenovoRx |
| NCT00040131 | Phase 2 | Jan 1, 2002 | Merck |
| NCT00001797 | Phase 2 | Jan 1, 1999 | National Cancer Institute (NCI) |
| NCT00001761 | Phase 1 | Feb 1, 1998 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03554434 | N/A | — | ARMO BioSciences |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ARMO BioSciences | For profit | 8 | 7 | 4 | 2013 |
| RenovoRx | For profit | 2 | 2 | 2 | 2005 |
| Eli Lilly | For profit | 1 | 1 | 1 | 2018 |
| Kaohsiung Medical University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Merck | For profit | 1 | 1 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1999 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1998 |
7 organizations
Page 1 / 1